Clinical Trial Update: Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing osteoporosis patients self-administering daily teriparatide with the Forteo B Pen; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Forteo (teriparatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2009-06-24